FDA Panel Recommends New Studies For Fujirebio’s Ovarian Cancer Test
This article was originally published in The Gray Sheet
Executive Summary
FDA should not clear Fujirebio's HE4 enzyme immunoassay kit and associated "risk of ovarian malignancy algorithm"(ROMA) until the firm demonstrates the test's ability to help community physicians triage patients for referral to gynecologic oncology specialists, according to the agency's Immunology Devices advisory panel
You may also be interested in...
A Compliant Abbott Channels More Funds Into Core Diagnostics R&D
Now that Abbott is in the final throes of a 1999 FDA consent degree, the company's core chemistry and immunoassay diagnostics unit says it has freed up some more funds for research and development
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.